Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The sodium-glucose cotransporter protein 2 (SGLT2) is a membrane protein primarily responsible for the reabsorption of glucose in the kidney. It is an electrogenic symporter that actively transports D-glucose across cell membranes by coupling its movement with sodium ions. Inhibitors of SGLT2 are used as antidiabetic agents, and emerging evidence suggests potential roles for these inhibitors in cancer therapy.
Inhibition of renal glucose reabsorption by blocking SGLT2 in proximal tubules, leading to increased urinary glucose excretion and reduced blood sugar levels.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-glucose cotransporter protein 2 (SGLT2).